NT-proBNP in cardiopulmonary resuscitated patients treated with mild therapeutic hypothermia is not independently associated with mortality: a retrospective observational study

BMC Anesthesiology

Monique C de Waard¹  Armand RJ Girbes¹  Angelique ME Spoelstra-de Man¹  Bob Smit¹ 

[1]Department of Intensive Care, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, Amsterdam, Netherlands

关键词: NT-proBNP;    Natriuretic peptides;    Mild therapeutic hypothermia;    Cardiac arrest;   

Others  :  1170513
DOI  :  10.1186/s12871-015-0023-y

 received in 2014-05-16, accepted in 2015-03-12,  发布年份 2015

【 摘 要 】

Background

In spite of the introduction of mild therapeutic hypothermia (MTH), mortality rates remain high in patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA). To date, no accurate and independent biomarker to predict survival in these patients exists. B-type natriuretic peptide (BNP) was found to provide both prognostic and diagnostic value in various cardiovascular diseases, including survival to hospital discharge in patients with ROSC. However, the biologically inactive counterpart of BNP, NT-proBNP, was found to be a more stable and accurate analyte. The current retrospective observational study investigates the value of NT-proBNP to predict 28-day mortality in post-CA patients treated with MTH, as well as the dynamics of NT-proBNP during MTH.

Methods

NT-proBNP levels were measured in post-CA patients cooled via cold intravenous saline infusion and water-circulating body wraps (Medi-Therm®, Gaymar). Plasma samples were obtained before cooling was started, at the start and end of the maintenance phase and at the end of rewarming.

Results

250 patients, admitted between 2009 and 2013, had NT-proBNP levels measured on ICU admission and were included for the evaluation of NT-proBNP as a prognostic marker. In the 28 days following ICU admission, 114 patients died (46%). Non-survivors had significantly higher NT-proBNP (median 1448 ng/l, IQR 366–4623 vs median 567 ng/1, IQR 148–1899; P < 0.001) levels on ICU admission. Unadjusted odds ratios for 28-day mortality were 1.7 (95% CI 0.8-3.5), 1.6 (0.8-3.3) and 3.6 (1.7-7.5) for increasing quartiles of NT-proBNP as compared to the lowest quartile. Adjusted odds ratios were 1.1 (95% CI 0.5-2.5), 1.1 (0.5-2.5) and 1.6 (0.7-3.8), respectively. A cut-off value of 834 ng/l achieved a sensitivity of 58% and a specificity of 58% to predict 28-day mortality. Of 113 patients, NT-proBNP values of each MTH phase were available and grouped in decreased or increased levels in time. Both decreases and increases of NT-proBNP values were observed during the MTH phases, but presence of either was not associated with outcome.

Conclusions

High NT-proBNP plasma concentrations on ICU admission are associated with high 28-day mortality in post-CA patients treated with MTH in a univariate analysis, but not in a multivariate analysis. Increases or decreases of NT-proBNP levels during MTH appear unrelated to 28 day mortality.

【 授权许可】

   
2015 Smit et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Peberdy MA, Callaway CW, Neumar RW, Geocadin RG, Zimmerman JL, Donnino M, et al.: Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010, 122:S768-86.
• [2]Berdowski J, Berg RA, Tijssen JG, Koster RW: Global incidences of out-of-hospital cardiac arrest and survival rates: Systematic review of 67 prospective studies. Resuscitation. 2010, 81:1479-87.
• [3]Scolletta S, Donadello K, Santonocito C, Franchi F, Taccone FS: Biomarkers as predictors of outcome after cardiac arrest. Expert Rev Clin Pharmacol. 2012, 5:687-99.
• [4]Sodeck GH, Domanovits H, Sterz F, Schillinger M, Losert H, Havel C, et al.: Can brain natriuretic peptide predict outcome after cardiac arrest? An observational study. Resuscitation. 2007, 74:439-45.
• [5]Nagao K, Mukoyama T, Kikushima K, Watanabe K, Tachibana E, Iida K, et al.: Resuscitative value of B-type natriuretic peptide in comatose survivors treated with hypothermia after out-of-hospital cardiac arrest due to cardiac causes. Circ J. 2007, 71:370-6.
• [6]Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med. 1998, 339:321-8.
• [7]Casals G, Ros J, Sionis A, Davidson MM, Morales-Ruiz M, Jimenez W: Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol. 2009, 297:H550-5.
• [8]Weidemann A, Klanke B, Wagner M, Volk T, Willam C, Wiesener MS, et al.: Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J. 2008, 409:233-42.
• [9]Due-Andersen R, Pedersen-Bjergaard U, Hoi-Hansen T, Olsen NV, Kistorp C, Faber J, et al.: NT-pro-BNP during hypoglycemia and hypoxemia in normal subjects: impact of renin-angiotensin system activity. J Appl Physiol. 2008, 104:1080-5.
• [10]LaPointe MC: Molecular regulation of the brain natriuretic peptide gene. Peptides. 2005, 26:944-56.
• [11]Ogawa T, de Bold AJ: Brain natriuretic Peptide production and secretion in inflammation. J Transplant. 2012, 2012:962347.
• [12]Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al.: Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006, 47:91-7.
• [13]Giannakoulas G, Hatzitolios A, Karvounis H, Koliakos G, Charitandi A, Dimitroulas T, et al.: N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. Angiology. 2005, 56:723-30.
• [14]Yip HK, Sun CK, Chang LT, Chen MC, Liou CW: Time course and prognostic value of plasma levels of N-terminal pro-brain natriuretic peptide in patients after ischemic stroke. Circ J. 2006, 70:447-52.
• [15]Etgen T, Baum H, Sander K, Sander D: Cardiac troponins and N-terminal pro-brain natriuretic peptide in acute ischemic stroke do not relate to clinical prognosis. Stroke. 2005, 36:270-5.
• [16]Ordonez-Llanos J, Collinson PO, Christenson RH: Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol. 2008, 101:9-15.
• [17]Heringlake M, Heide C, Bahlmann L, Eichler W, Pagel H, Schmucker P, et al.: Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers. J Appl Physiol. 2004, 97:173-9.
• [18]Arjamaa O, Nikinmaa M: Hypoxia regulates the natriuretic peptide system. Int J Physiol Pathophysiol Pharmacol. 2011, 3:191-201.
• [19]Yildiz S, Uzun G, Uz O, Ipcioglu OM, Kardesoglu E, Ozcan O: N-terminal pro-B-type natriuretic peptide levels increases after hyperbaric oxygen therapy in diabetic patients. Clin Invest Med. 2008, 31:E231-5.
• [20]de Graaff AE, Dongelmans DA, Binnekade JM, de Jonge E: Clinicians’ response to hyperoxia in ventilated patients in a Dutch ICU depends on the level of FiO2. Intensive Care Med. 2011, 37:46-51.
• [21]Cornet AD, Kooter AJ, Peters MJ, Smulders YM: Supplemental oxygen therapy in medical emergencies: more harm than benefit? Arch Intern Med. 2012, 172:289-90.
• [22]Spindelboeck W, Schindler O, Moser A, Hausler F, Wallner S, Strasser C, et al.: Increasing arterial oxygen partial pressure during cardiopulmonary resuscitation is associated with improved rates of hospital admission. Resuscitation. 2013, 84:770-5.
• [23]Valette X, Lemoine S, Allouche S, Gerard JL, Hanouz JL: Effect of lipopolysaccharide, cytokines, and catecholamines on brain natriuretic peptide release from human myocardium. Acta Anaesthesiol Scand. 2012, 56:860-5.
• [24]Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al.: Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med. 2013, 369:2197-206.